natgillin/translations-raw huggingface dataset:
An anti-Notch1 NRR antibody for use according to claim 17, wherein the disorder is associated with an activating mutation in a Notch1 amino acid sequence. 
Anti-Notch1-NRR-protutijelo za uporabu prema zahtjevu 17, naznačeno time, da je poremećaj povezan s aktiviranjem mutacije u Notch1-amino kiselinskoj sekvenci.
A composition comprising an anti-Notch1 NRR antibody as in any one of claims 1-11 and a pharmaceutical carrier. 
Sastav, naznačen time, da obuhvaća anti-Notch1-NRR-protutijelo prema bilo kojem zahtjevu od 1 do 11 i farmaceutski nosač.
The method of claim 1, wherein the L1 signaling data includes notch start information indicating a start position of a notch band existing in the signal frame. 
Metoda iz patentnog zahtjeva 1, pri čemu signalni podatak L1 uključuje informaciju širine obilježja koja ukazuje širinu polja obilježja koje postoji u okviru signala.
means (103) for building a signal frame including preamble symbols and symbols of the data slices, wherein the preamble symbols include L1 blocks and each of the L1 blocks has at least one L1 TI block and L1 header; means (104) for modulating the signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; and means (105) for transmitting the modulated signal frame, 
sredstvo (103) za izgradnju okvira signala uključujući simbole početnog niza i simbole kodiranog PLP podatka, pri čemu simboli početnog niza uključuju barem jedan L1 TI blok i L1 zaglavlje, pri čemu su barem jedan L1 TI blok i L1 zaglavlje ponovljeni u simbolu početnog niza; sredstvo (104) za moduliranje okvira signala ortogonalnom modulacijskom metodom u frekvencijskoj domeni, OFDM; i sredstvo (105) za prijenos moduliranog okvira signala, pri čemu L1 zaglavlje uključuje L1 TI oblik informacije naznačujući dubinu umetanja vremena signalnog podatka L1.
A method for receiving a broadcasting signal, the method comprising: 
Metoda za prijam emitiranog signala, metoda obuhvaća:
demodulating the received broadcasting signal by an Orthogonal Frequency Division Multiplexing, OFDM, method; 
demoduliranje primljenog emitiranog signala ortogonalnom modulacijskom metodom u frekvencijskoj domeni, OFDM;
selectively time-deinterleaving the preamble symbols including the at least one L1 TI block by a row-column twisted fashion, wherein the row-column twisted fashion comprises input L1 signaling data cells serially written into an interleaving memory in a diagonal direction, and serially read out row-wise, without considering pilot positions; 
selektivno raspletanje vremena simbola početnog niza uključujući barem jedan L1 TI blok na način prelamanja redova-stupaca, pri čemu način prelamanja redova-stupaca obuhvaća unos u podatkovne stanice signalnih podataka L1 serijski upisane u memoriju umetanja u dijagonalnom smjeru, i serijsko očitavanje u smjeru redova, bez razmatranja pozicija pilota;
means (r104) for demodulating the received broadcasting signal by an Orthogonal Frequency Division Multiplexing, OFDM, method; 
sredstvo (r104) za demoduliranje primljenog emitiranog signala ortogonalnom modulacijskom metodom u frekvencijskoj domeni, OFDM;
A method for separating collagen from an animal tissue, thereby obtaining collagen as 10 to 20% of the initial tissue weight, comprising 
Postupak za odvajanje kolagena iz životinjskog tkiva, kojim se dobiva kolagen kao 10 do 20% od početne mase tkiva, naznačen time da se sastoji od
thoroughly washing a porcine-isolated bone tissue with distilled water, ethanol and acetone; 
temeljitog ispiranja koštanog tkiva izoliranog od svinje s destiliranom vodom, etanolom i acetonom;
cutting the bone tissue into a doughnut shape and storing it at -20°C; 
rezanja koštanog tkiva u oblik krafne i njegove pohrane kod -20°C;
processing the bone tissue into a powder having a particle size of 1 to 500 micrometers, in order to separate collagen from the bone tissue; 
obrade koštanog tkiva u prah koji ima veličinu čestica od 1 do 500 mikrometara, kako bi se odvojio kolagen od koštanog tkiva;
washing the bone tissue powder with ethanol and distilled water; 
ispiranja koštanog tkiva u prahu sa etanolom i destiliranom vodom;
treating the bone powder with pepsin (10 to 50:1 ratio of the tissue:pepsin, and dissolved in 0.1N HCl prior to use), after overnight treatment; 
obrade koštanog tkiva u prahu sa pepsinom (omjer tkivo:pepsin od 10 do 50:1, te otopljenog u 0.1N HCl prije upotrebe), nakon obrade tijekom noći;
applying a final concentration of 0.5 to 0.8M NaCl to the separated and stored supernatant, followed by treatment at 4°C for 4 hours to 1 day; removing a precipitate and collecting a supernatant, after centrifugation (12,000g, 30 min and 4°C); titrating the supernatant under neutral conditions and adding NaCl to make a final concentration of the solution to 1.6M NaCl; 
primjene konačne koncentracije od 0.5 do 0.8M NaCl na izdvojeni i pohranjeni supernatant, te zatim obrade kod 4°C tijekom 4 sata do 1 dana; uklanjanja taloga i prikupljanja supernatanta, nakon centrifugiranja (12,000g, 30 min i 4°C); titracije supernatanta pod neutralnim uvjetima i dodavanja NaCl da se dobije konačna koncentracija otopine od 1.6M NaCl;
thoroughly washing a porcine-isolated cartilage tissue with distilled water, ethanol and acetone; 
temeljitog ispiranja tkiva hrskavice izoliranog od svinje s destiliranom vodom, etanolom i acetonom;
processing the cartilage tissue into a powder having a particle size of 1 to 500 micrometers, in order to separate collagen from the cartilage tissue; 
obrade tkiva hrskavice u prah koji ima veličinu čestica od 1 do 500 mikrometara, kako bi se odvojio kolagen od tkiva hrskavice;
washing the cartilage tissue powder with ethanol and distilled water; 
ispiranja tkiva hrskavice u prahu sa etanolom i destiliranom vodom;
washing the overnight-treated cartilage powder once or twice with 0.1N HCl; 
ispiranja preko noći obrađenog praha hrskavice jednom ili dva puta sa 0.1N HCl;
treating the cartilage powder with pepsin (10 to 50:1 ratio of the tissue:pepsin, and dissolved in 0.1N HCl prior to use), after overnight treatment; 
obrade praha hrskavice sa pepsinom (omjer tkivo:pepsin od 10 do 50:1, te otopljenog u 0.1N HCl prije upotrebe), nakon obrade tijekom noći;
removing a precipitate and collecting a supernatant, after centrifugation (12,000g, 30 min and 4°C); 
uklanjanja taloga i prikupljanja supernatanta, nakon centrifugiranja (12,000g, 30 min i 4°C);
titrating the supernatant under neutral conditions and adding NaCl to make a final concentration of the solution to 1.6M NaCl; 
titracije supernatanta pod neutralnim uvjetima i dodavanja NaCl da se dobije konačna koncentracija otopine od 1.6M NaCl;
adding 1N HCl to the resuspended solution in an amount of 1mL:100 mL ratio to accomplish complete resuspension, followed by titration at 4°C under neutral conditions; 
dodavanja 1N HCl u resuspendiranu otopinu u količini sa omjerom 1mL:100 mL da se ostvari potpuna resuspenzija, te zatim slijedi titracija kod 4°C pod neutralnim uvjetima;
standing the thus-titrated solution at a temperature of 30 to 37°C for 4 hours to 1 day, followed by centrifugation; and 
odležavanja tako titrirane otopine kod temperature od 30 do 37°C tijekom 4 sata do 1 dana, te potom centrifugiranja; te
thoroughly washing a porcine-isolated skin tissue with distilled water and ethanol, followed by storage at -20°C; 
temeljitog ispiranja kožnog tkiva izoliranog od svinje s destiliranom vodom i etanolom, te potom pohranjivanja na -20°C;
processing the skin tissue into a section having a thickness of 500 micrometers to 5 mm, in order to separate collagen from the skin tissue; 
obrade kožnog tkiva u dijelove koji imaju debljinu od 500 mikrometara do 5 mm, kako bi se odvojio kolagen od kožnog tkiva;
placing the tissue section in a net having a lattice size of 200 to 500 micrometers and washing with ethanol and distilled water; 
postavljanja dijelova tkiva u mrežu koja ima rešetku veličine 200 do 500 mikrometara i ispiranja sa etanolom i destiliranom vodom;
treating the thus-washed skin tissue with pepsin (10 to 50:1 ratio of the tissue:pepsin, and dissolved in 0.1N HCl prior to use); 
obrade tako ispranog kožnog tkiva sa pepsinom (omjer tkivo:pepsin od 10 do 50:1, te otopljenog u 0.1N HCl prije upotrebe);
additionally adding NaCl to the collected supernatant to a final concentration of 2.6M NaCl, followed by standing at 4°C for 4 hours to 1 day; 
ponovnog dodavanja NaCl u prikupljeni supernatant do konačne koncentracije od 2.6M NaCl, nakon čega se ostavlja da odleži na 4°C tijekom 4 sata do 1 dana;
processing the tendon/ligament tissue into a section having a thickness of 500 micrometers to 5 mm, in order to separate collagen from the tendon/ligament tissue; 
obrade tkiva tetive/ligamenta u dijelove koji imaju debljinu od 500 mikrometara do 5 mm, kako bi se odvojio kolagen od tkiva tetive/ligamenta;
washing the tissue section with ethanol and distilled water; 
ispiranja dijelova tkiva sa etanolom i destiliranom vodom;
treating the thus-washed tendon/ligament tissue with pepsin (10 to 50:1 ratio of the tissue:pepsin, and dissolved in 0.1N HCl prior to use); 
obrade tako ispranog tkiva tetive/ligamenta sa pepsinom (omjer tkivo:pepsin od 10 do 50:1, te otopljenog u 0.1N HCl prije upotrebe);
adding 1N HCl to the resuspended solution in an amount of 1mL: 100 mL ratio to accomplish complete resuspension, followed by titration at 4°C under neutral conditions; 
dodavanja 1N HCl u resuspendiranu otopinu u količini u omjeru od 1mL: 100 mL da se ostvari potpuna resuspenzija, te zatim slijedi titracija kod 4°C pod neutralnim uvjetima;
A method for preparing a collagen solution from an animal tissue, comprising, upon final treatment of collagen: treating a collagen solution as prepared according to any of the claims 1 to 4 having a predetermined concentration under a neutral condition at 4°C, followed by overnight treatment at a temperature of 30 to 35°C; 
Postupak za dobivanje otopine kolagena iz životinjskog tkiva, naznačen time da se, nakon konačne obrade kolagena sastoji od: obrade otopine kolagena koja je dobivena prema bilo kojem zahtjevu od 1 do 4 koja ima prethodno određenu koncentraciju kod neutralnog stanja kod 4°C, te zatim slijedi obrada preko noći kod temperature od 30 do 35°C;
A compound which is: or a single isomer or tautomer thereof where the compound is optionally as a pharmaceutically acceptable salt and additionally optionally as a hydrate and additionally optionally as a solvate thereof; for use in combination with one or more treatments independently selected from one or more chemotherapeutic agents selected from the group consisting of a platin, a taxane, rapamycin, and erlotinib for the treatment of cancer. 
Spoj koji je: [image] ili njegov pojedinačni izomer ili tautomer gdje je spoj izborno kao njegova farmaceutski prihvatljiva sol i dodatno izborno kao hidrat i dodatno izborno kao solvat; za uporabu u kombinaciji sa jednim ili više tretmana nezavisno izabranih od jednog ili više kemoterapeutskih sredstavaizabranih iz grupe koju čine platin, taksan, rapamicin i erlotinib za liječenje kancera.
The compound of claim 1 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is rapamycin. 
Spoj prema patentnom zahtjevu 1, naznačen time što je tretman jedno kemoterapeutsko sredstvo, gdje je kemoterapeutsko sredstvo rapamicin.
The compound of claim 1 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is carboplatin. 
Spoj prema patentnom zahtjevu 1, naznačen time što je tretman jedno kemoterapeutsko sredstvo, gdje je kemoterapeutsko sredstvo karboplatin.
The compound of claim 1 where the treatment is one chemotherapeutic agent where the chemotherapeutic agent is erlotinib. 
Spoj prema patentnom zahtjevu 1, naznačen time što je tretman jedno kemoterapeutsko sredstvo, gdje je kemoterapeutsko sredstvo erlotinib.
The compound of claim 1 where the cancer is selected from prostate cancer, non-small cell lung cancer, and breast cancer. 
Spoj prema patentnom zahtjevu 1, naznačen time što je kancer izabran od kancera prostate, nesitnostaničnog kancera pluća i kancera dojke.
The compound of claim 1 where the chemotherapeutic agent is taxol and the cancer is prostate cancer. 
Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo taksol i kancer je kancer prostate.
The compound of claim 1 where the chemotherapeutic agent is rapamycin and the cancer is prostate cancer. 
Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo rapamicin i kancer je kancer prostate.
The compound of claim 1 where the chemotherapeutic agent is carboplatin and the cancer is non-small cell lung cancer. 
Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo karboplatin i kancer je nesitnostanični kancer pluća.
The compound of claim 1 where the chemotherapeutic agent is erlotinib and the cancer is breast cancer. 
Spoj prema patentnom zahtjevu 1, naznačen time što je kemoterapeutsko sredstvo erlotinib i kancer je kancer dojke.
a top mold (11) and a bottom mold for placing a green tire (T); 
gornji kalup (11) i donji kalup za stavljanje neobrađene gume (T);
a top mold mounting member (20) connected to said top mold; 
dio za namještanje gornjeg kalupa (20) spojen na taj gornji kalup;
a ball screw shaft (55a) having a vertically aligned shaft center; 
kuglasta navojna šipka (55a) koja ima okomito postavljeno središte šipke;
a driving mechanism (59) for rotating said ball screw shaft switchably between normal direction and reverse direction, wherein said driving mechanism is provided with an inverter motor (52); 
pogonski mehanizam (59) za rotaciju te kuglaste navojne šipke naizmjenično između normalnog smjera i smjera unatrag, gdje taj pogonski mehanizam ima inverter motor (52);
an inverter (52a) capable of servo-locking said inverter motor; 
inverter (52a) koji može servo-zaključati taj inverter motor;
an excitation-free electromagnetic brake (57) connected directly to said ball screw shaft to fix said ball screw shaft and provided independently from said driving mechanism; and a control device (80) configured to execute a brake operation switching control for switching between operation and release of the electromagnetic brake, and a motor power control for powering on and off said inverter motor by controlling said inverter. 
ne-ekscitirana elektromagnetska kočnica (57) spojena izravno za tu kuglastu navojnu šipku da fiksira tu kuglastu navojnu šipku i dolazi nezavisno od pogonskog mehanizam; i kontrolni uređaj (80) konfiguriran da provede kontrolu rada kočnice za promjenu između rada i oslobađanja elektromagnetske kočnice, i kontrolu rada motora za uključivanje i isključivanje tog inverter motora preko kontrole tog invertera.
The tire vulcanizer according to claim 2, wherein said control device further is configured to operate said electromagnetic brake to fix said ball screw shaft under the condition that said inverter motor allows said top mold mounting member to perform retained operation to stop in the elevating direction, and thereafter powering off said inverter motor by controlling said inverter. 
Stroj za vulkanizaciju gume prema zahtjevu 2, pri čemu taj kontrolni uređaj je dalje konfiguriran da upravlja elektromagnetskom kočnicom tako da fiksira tu kuglastu navojnu šipku pod uvjetom da taj inverter motor omogućava dijelu za namještanje gornjeg kalupa da se zadrži u radu u zaustavljenom dignutom smjeru, i zatim da isključi taj inverter motor preko kontrole invertera.
The tire vulcanizer according to claim 4, wherein said measuring device is adapted to measure the elevating position of said top mold mounting member not through said driving mechanism. 
Stroj za vulkanizaciju gume prema zahtjevu 4, pri čemu je taj mjerni uređaj adaptiran da ne mjeri podignuti položaj dijela za podizanje gornjeg kalupa preko pogonskog mehanizma.
The tire vulcanizer according to claim 2, wherein, when said ball screw shaft is fixed with said electromagnetic brake, and if said control device judges that said top molt mounting member has lowered based on the elevating position measured by said measuring device, said control device controls said inverter to servo-lock said inverter motor. 
Stroj za vulkanizaciju gume prema zahtjevu 2, pri čemu, kada je ta kuglasta navojna šipka fiksirana elektromagnetskom kočnicom, i ako kontrolni uređaj procijeni da se dio za namještanje gornjeg kalupa spustio na temelju izmjerenog podignutog položaja od strane mjernog uređaja, taj kontrolni uređaj kontrolira inverter da servo-zaključa inverter motor.
The tire vulcanizer according to claim 2, wherein the tire vulcanizer further comprises an obstacle detection device (90) for detecting whether an obstacle is within said mold, and wherein, when said ball screw shaft is fixed with said electrocmagnetic brake, and if said control device judges that said top mold mounting member has lowered based on the elevating position measured by said measuring device, said control device controls said inverter to servo-lock said inverter motor, and thereafter if said control device judged absence of obstacle with said obstacle detection device, said control device puts said mold into mold closing position by controlling said inverter. 
Stroj za vulkanizaciju gume prema zahtjevu 2, pri čemu stroj za vulkanizaciju gume dalje obuhvaća uređaj za otkrivanje prepreka (90) za otkrivanje postoji li prepreka unutar kalupa, i pri čemu, kada je ta kuglasta navojna šipka fiksirana elektromagnetskom kočnicom, i ako kontrolni uređaj procijeni da se dio za namještanje gornjeg kalupa spustio na temelju izmjerenog podignutog položaja od strane mjernog uređaja, taj kontrolni uređaj kontrolira inverter da servo-zaključa inverter motor, i zatim ako taj kontrolni uređaj pomoću uređaja za otkrivanje prepreka utvrdi da nema prepreka, taj kontrolni uređaj stavlja kalup u položaj za zatvaranje kalupa preko kontrole invertera.
operating an electromagnetic brake (57) independently from operating said inverter motor, under to condition that the inverter motor allows the top mold mounting member to perform retained operation to stop in the elevating direction, to fix the ball screw shaft, and thereafter powering off the inverter motor; and carrying out a motor power control for powering on and off said inverter motor by controlling said inverter. 
upravljanje elektromagnetskom kočnicom (57) nezavisno od upravljanja tim inverter motorom, pod uvjetom da inverter motor omogućava dijelu za namještanje gornjeg kalupa da se zadrži u radu u zaustavljenom dignutom smjeru, da fiksira kuglastu navojnu šipku, i zatim isključivanje inverter motora; i provođenje kontrole rada motora za uključivanje i isključivanje tog inverter motora preko kontrole invertera.
The brake control method for the tire vulcanizer according to claim 8, wherein if an elevating speed of the top mold mounting member is judged to be higher than a predetermined limiting speed, the electromagnetic brake is operated to fix the ball screw shaft. 
Postupak kontrole kočenja za stroj za vulkanizaciju gume prema zahtjevu 8, pri čemu, ako se procijeni da je brzina podizanja dijela za namještanje gornjeg kalupa veća od one ograničavajuće unaprijed određene brzine, pokreće se elektromagnetsku kočnicu da fiksira kuglastu navojnu šipku.
The brake control method for the tire vulcanizer according to claim 8, wherein when the ball screw shaft is fixed with the electromagnetic brake, and if the top mold mounting member is judges to have lowered, the inverter motor is servo-locked. 
Postupak kontrole kočenja za stroj za vulkanizaciju gume prema zahtjevu 8, pri čemu, kada je kuglasta navojna šipka fiksirana elektromagnetskom kočnicom, i ako se procijeni da se dio za namještanje gornjeg kalupa spustio, inverter motor se servo-zaključava.
The brake control method for the tire vulcanizer according to claim 8, wherein when the ball screw shaft is fixed by operating the electromagnetic brake, and if the top mold mounting member is judged to have lowered, the inverter motor is servo-locked, and thereafter if absence of obstacle within the mold is judged, the mold is put into mold closing position. 
Postupak kontrole kočenja za stroj za vulkanizaciju gume prema zahtjevu 8, pri čemu, kada je kuglasta navojna šipka fiksirana radom elektromagnetske kočnice, i ako se procijeni da se dio za namještanje gornjeg kalupa spustio, inverter motor se servo-zaključava, i zatim ako se odredi da nema prepreka u kalupu, kalup se stavlja u položaj za zatvaranje kalupa.
The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11 for use in the prevention or treatment of dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression or allergic rhinitis. 
Derivat fenilpirazola ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 11 naznačen time da je za upotrebu za sprječavanje ili liječenje demencije, Alzheimerove bolesti, poremećaja hiperaktivnosti sa nedostatkom pažnje, shizofrenije, epilepsije, konvulzija, poremećaja u prehrani, pretilosti, dijabetesa, hiperlipidemije, poremećaja spavanja, narkolepsije, sindroma apneje u snu, poremećaja dnevnog ritma, depresije ili alergijskog rinitisa.
A hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid according to claim 1 or 2, wherein said salt has a degree of crystallinity greater than about 20%, preferably greater than about 90%. 
Hemifumaratna sol od 1-(4-{1-[(E)-4-cikloheksil-3-trifluorometil-benziloksiimino]-etil}-2-etil-benzil)-azetidin-3-karboksilne kiseline prema zahtjevu 1, naznačena time, da spomenuta sol ima stupanj kristaliniteta veći od oko 90%.
A hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid according to any of claims 1 to 4 wherein the salt comprises a Crystalline Form A, wherein the Crystalline Form A has the following FT-Raman spectrum: 
Kristalni oblik A od hemifumaratne soli od 1-(4-{1-[(E)-4-cikloheksil-3-trifluorometil-benziloksiimino]-etil}-2-etil-benzil)-azetidin-3-karboksilne kiseline prema bilo kojem zahtjevu od 4 do 8, naznačen time, da kristalni oblik ima uzorak difrakcije praha X-zraka sa specifičnim vršnim vrijednostima nabrojanima u Tablici 1:
A sterile vaccine comprising an inactivated influenza virus antigen, wherein the vaccine contains no mercurial preservative, no antibiotic, no formaldehyde and no egg-derived materials. 
Sterilno cjepivo koje sadrži inaktivirani antigen virusa influence, naznačeno time da cjepivo ne sadrži konzervanse sa živom, ne sadrži antibiotik, ne sadrži formaldehid i ne sadrži materijale dobivene od jaja.
The vaccine of claim 8 wherein the adjuvant is an oil-in-water emulsion. 
Cjepivo prema zahtjevu 8 naznačeno time da je adjuvant emulzija ulja u vodi.
The vaccine of claim 9, wherein the oil-in-water emulsion comprises squalene. A process for preparing a sterile influenza virus antigen formulation which contains no mercurial preservative, no antibiotic, no formaldehyde and no egg-derived materials, comprising the steps of: (i) growing influenza virus in a cell culture system, in the absence of egg-derived materials and of antibiotics; (ii) inactivating the influenza viruses grown in step (i), in the absence of formaldehyde; and (iii) preparing a vaccine antigen formulation from the inactivated influenza viruses, in the absence of thimerosal. 
Postupak za dobivanje sterilne formulacije antigena virusa influence koja ne sadrži konzervanse sa živom, ne sadrži antibiotik, ne sadrži formaldehid i materijale dobivene od jaja, naznačen time da sadrži slijedeće korake: (i) uzgajanje virusa influence u sustavu stanične kulture, bez prisutnosti materijala dobivenih od jaja i antibiotika; (ii) inaktiviranje virusa influence uzgojenih u koraku (i), bez prisutnosti formaldehida; te (iii) dobivanja formulacije antigena cjepiva iz inaktiviranih virusa influence, bez prisutnosti timerosala.